Format

Send to

Choose Destination
JCI Insight. 2018 Jul 26;3(14). pii: 120594. doi: 10.1172/jci.insight.120594. eCollection 2018 Jul 26.

FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.

Author information

1
Department of Pathology and.
2
Division of Medical Oncology, Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA.
3
University of Colorado School of Medicine, RNA Bioscience Initiative, Aurora, Colorado, USA.
4
Division of Endocrinology, Metabolism, & Diabetes, Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA.
5
Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York, USA.
6
Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA.
7
Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
8
Department of Surgery, MSKCC, New York, New York, USA.
9
Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, New York, USA.

Abstract

Obesity increases breast cancer mortality by promoting resistance to therapy. Here, we identified regulatory pathways in estrogen receptor-positive (ER-positive) tumors that were shared between patients with obesity and those with resistance to neoadjuvant aromatase inhibition. Among these was fibroblast growth factor receptor 1 (FGFR1), a known mediator of endocrine therapy resistance. In a preclinical model with patient-derived ER-positive tumors, diet-induced obesity promoted a similar gene expression signature and sustained the growth of FGFR1-overexpressing tumors after estrogen deprivation. Tumor FGFR1 phosphorylation was elevated with obesity and predicted a shorter disease-free and disease-specific survival for patients treated with tamoxifen. In both human and mouse mammary adipose tissue, FGF1 ligand expression was associated with metabolic dysfunction, weight gain, and adipocyte hypertrophy, implicating the impaired response to a positive energy balance in growth factor production within the tumor niche. In conjunction with these studies, we describe a potentially novel graft-competent model that can be used with patient-derived tissue to elucidate factors specific to extrinsic (host) and intrinsic (tumor) tissue that are critical for obesity-associated tumor promotion. Taken together, we demonstrate that obesity and excess energy establish a tumor environment with features of endocrine therapy resistance and identify a role for ligand-dependent FGFR1 signaling in obesity-associated breast cancer progression.

KEYWORDS:

Breast cancer; Endocrinology; Obesity; Oncology; growth factors

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center